Overview
publication venue for
- Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions. 41:4218-+. 2023
- Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. 41:3712-+. 2023
- A national analysis evaluating the role of neoadjuvant chemoradiotherapy in upper esophageal cancer 2023
- A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer 2023
- A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab plus chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA) 2023
- Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab plus carboplatin plus nabpaclitaxel (A plus CnP) 2023
- EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC). 2023
- Estrogen receptor positive breast cancer in an Afro-Caribbean cohort. 2023
- Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC) 2023
- Nationwide phase II randomized controlled trial of low-dose ibuprofen vs placebo for cancer-related cognitive impairment (CRCI) 2023
- PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors. 2023
- Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial 2023
- Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC) 2023
- Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC) 2023
- Safety and efficacy of time restricted eating (TRE) in improving response to immunotherapy in patients with head and neck cancer (HNSCC). 2023
- Survival analysis comparing neoadjuvant chemoradiotherapy versus perioperative chemotherapy for locoregional gastric cancer 2023
- Association of peripheral blood neutrophil-lymphocyte ratio (NLR) and red cell distribution width (RDW) with immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC). 2023
- Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience. 2023
- Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation. 2023
- Genomic analysis from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy. 2023
- Germline genetic testing of patients with penile carcinoma. 2023
- Neural network analysis of tumor and germline profiling to predict survival of muscleinvasive bladder cancer following radical cystectomy: An analysis of the Cancer Genome Atlas (TCGA). 2023
- Pathologic response with neoadjuvant chemotherapy, immunotherapy, and chemoimmunotherapy for muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis. 2023
- Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma. 2023
- Phase II trial of lurbinectedin combined with avelumab as maintenance therapy for metastatic urothelial carcinoma with stable or responding disease following platinumbased chemotherapy. 2023
- Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT). 2023
- Prediction of risk factors associated with readmission after robotic esophagectomy. 2023
- Reducing preventable ED visits in patients with advanced NSCLC: Collective insights from three cancer centers. 2022
- Acquired EGFR-resistant mutations in non-small cell lung cancer (NSCLC). 2022
- Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency. 2022
- Efficacy of the novel treatments of BCC with bone metastasis. 2022
- Literature on target therapy of malignant melanoma. 2022
- MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib plus dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC). 2022
- Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20). 2022
- Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84). 2022
- Phase 2 pilot trial of RRx-001 as an anti-mucositis agent in patients with head and neck cancer treated with chemoradiation (PREVLAR). 2022
- Raising the level of cancer care: Feasibility and reported benefit of a virtual tumor board. 2022
- The impact of COVID-19 infection on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors 2022
- The safety and efficacy of immune checkpoint inhibitor rechallenge after immune-related adverse events in stage IV NSCLC patients. 2022
- Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. 40. 2022
- Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study 2022
- AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). 2021
- Association of the presence of estrogen and progesterone receptors in uterine carcinosarcoma with improved survival and increased immunogenicity. 2021
- Atezolizumab in first-line treatment of metastatic nonsquamous non-small cell lung cancer in the real-world setting. 2021
- CNS activity of poziotinib in NSCLC with exon 20 insertion mutations. 2021
- Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC). 2021
- Exploring molecular profiles of uterine carcinosarcoma with alterations in the chromatin remodeling pathway. 2021
- FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)-Phase III double-blind placebo controlled multinational study. 2021
- Feasibility of a telemedicine lifestyle-based rehabilitation program (HEAL) for gynecologic cancer patients. 2021
- Final survival follow-up and translational associations using interval indirect immunization with oregovomab (O) and poly ICLC in patients (pts) with recurrent platinum-resistant ovarian cancer (PROC). 2021
- Immune-response markers and actual response to immune-oncology therapy in uterine serous carcinoma. 2021
- Interprofessional care team practices and perspectives on immuno-oncology (IO) therapies for metastatic non-small cell lung cancer (mNSCLC): Insights from a nationwide survey. 2021
- Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. 2021
- Molecular determinants of response to immune-oncology therapy in uterine carcinosarcoma. 2021
- Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150. 2021
- Population pharmacokinetics (Pop PK) of MYL-1402O (a proposed biosimilar to bevacizumab) and reference product (Avastin) in patients with nonsquamous non-small cell lung cancer (nsNSCLC). 2021
- Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). 2021
- Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers. 2021
- A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma. 2021
- CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions-A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). 2021
- Phase II/III study of SM-88 in patients with metastatic pancreatic cancer 2021
- Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. 38:3494-+. 2020
- Defining high-quality NSCLC care at US cancer centers. 2020
- Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline. 38:2570-+. 2020
- Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer. 38:2530-+. 2020
- A phase III trial-in-progress called REPLATINUM that compares RRx-001+a platinum doublet to a platinum doublet in third-line or beyond small cell lung cancer. 2020
- Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations. 2020
- Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial. 2020
- Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC). 2020
- Clinicopathologic analysis of MMR gene mutations and uterine adenocarcinomas: An updated population-based study. 2020
- Clinicopathologic and molecular genetic comparison of primary uterine serous adenocarcinomas from African American and Caucasian women. 2020
- Gender disparities in hormone positive lung cancer. 2020
- IMpower150: Exploratory analysis of brain metastases development. 2020
- Is there a genomic fingerprint of Radon (Rn)-induced lung cancer (LC)? Comparison of genomic alterations in LC specimens from high and low Rn zones. 2020
- Molecular features of gliomas with high tumor mutational burden. 2020
- Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. 2020
- The impact of therapeutic mediastinal radiation on stent healing in cancer patients: An optical coherence tomography study. 2020
- What constitutes high-quality NSCLC care? Overarching quality considerations for improving NSCLC care at US cancer centers. 2020
- Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study. 38:1030-+. 2020
- A phase II study of nab-paclitaxel plus ramucirumab for the second-line treatment of patients with metastatic gastroesophageal cancer 2020
- Phase II clinical trial of novel agent PBI-05204 in patients with metastatic pancreatic adenocarcinoma (mPDA) 2020
- Tumor downsizing following neoadjuvant therapy for borderline-resectable pancreatic adenocarcinoma 2020
- Eliminating Postoperative Radiation to the Pathologically Node-Negative Neck: Long-Term Results of a Prospective Phase II Study. 37:2548-+. 2019
- A novel drug to treat advanced melanoma. 2019
- Association betweenBRCA1 and BRCA2 mutations and prognosis in women with endometrial carcinoma. 2019
- Effect of early nutrition intervention on advanced nasopharyngeal carcinoma patients receiving chemoradiotherapy. 2019
- Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3. 2019
- Factors associated with extended survival for patients with platinum-resistant ovarian cancer treated with modified vaccinia oncolytic virotherapy. 2019
- IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets). 2019
- Initial breast cancer consult: Improving satisfaction and impact on distress. 2019
- MDNA55: A locally administered IL4 guided toxin as a targeted treatment for recurrent glioblastoma. 2019
- Predictors of mortality following cardiac surgery for carcinoid heart disease. 2019
- Recurrence and survival after robotic-assisted radical hysterectomy (RRH) for early-stage cervical cancer (CC): Experience may matter. 2019
- Recurrence rates in cervical cancer patients treated with abdominal versus minimally invasive radical hysterectomy: A multi-institutional analysis of 700 cases. 2019
- The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma. 2019
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. 36:2251-+. 2018
- IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab plus carboplatin plus paclitaxel or nab-paclitaxel vs carboplatin plus nab-paclitaxel as 1L therapy in advanced squamous NSCLC. 2018
- A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. 2018
- A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer 2018
- Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung 2018
- Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM). 2018
- Chronic thrombocytopenia in cancer patients: Impact on percutaneous coronary intervention and antiplatelet therapy. 2018
- Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study 2018
- Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3 2018
- First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP. 2018
- Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML). 2018
- Metabolic status of BRCA1 mutation carriers 2018
- Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) plus chemotherapy (chemo) +/- bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. 2018
- Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) plus chemotherapy (chemo) +/- bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC). 2018
- Phase 1b study of oncolytic vaccinia virus GL-ONC1 in recurrent ovarian cancer (ROC). 2018
- Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. 2018
- Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK plus advanced NSCLC (aNSCLC). 2018
- TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort. 2018
- Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study. 2018
- A phase 3b safety study of fixed-dose durvalumab plus tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A. 2018
- Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. 35:3591-+. 2017
- Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. 35:2885-+. 2017
- B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy 2017
- Enhancing clinician confidence on the therapeutic management of non-small cell lung cancer (NSCLC) through continuing medical education (CME). 2017
- IMpower132: A phase III clinical program-1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC. 2017
- Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy 2017
- Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. 35:1387-+. 2017
- A method to integrate an institutional database with multiple practice EHRs. 2017
- Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. 34:4079-+. 2016
- Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. 34:2858-+. 2016
- A novel live cell platform diagnostic utilizing phenotypic biomarkers for assessing prostate cancer aggressiveness. 2016
- E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process. 2016
- Effects of risk-reducing surgery on libido, self-image, and psychological status among BRCA mutation carriers. 2016
- Lifestyle issues affecting health and well-being of BRCA mutation carriers. 2016
- The Spruce clinical trial: Double-blind randomized phase II trial of carboplatin and pemetrexed plus /- apatorsen in patients with previously untreated stage IV non-squamous non-small-cell lung cancer. 2016
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. 34:661-+. 2016
- A live cell microfluidics device utilizing phenotypic biomarkers for prostate cancer. 2016
- A non-invasive urine exosome gene expression assay (ExoIntelliScore Prostate) to predict pathologic stage and grade in the prostatectomy specimen. 2016
- A phase II study of the combination of BKM120 (buparlisib) and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM). 2015
- A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK plus non-small-cell lung cancer (NSCLC) US/Canadian population who had progressed on crizotinib (NP28761). 2015
- Continued evaluation of a 31-gene expression profile test (GEP) for prediction of distant metastasis (DM) in cutaneous melanoma (CM) 2015
- Disturbances in quality of life among BRCA mutation carriers. 2015
- Efficacy and safety of the ALK inhibitor alectinib in ALK plus non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673). 2015
- FPGS expression to predict overall survival in non-small cell lung cancer patients treated with pemetrexed. 2015
- Alternative Strategy to Achieve Increased Overall Survival and Better Quality of Life in Patients With Second-Line Advanced Non-Small-Cell Lung Cancer 2015
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer. 32:4012-U160. 2014
- First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) 2014
- Pelvic sentinel lymph node status and risk of aortic nodal metastasis in patients with endometrial cancer. 2014
- Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N. 2014
- Phase II study of FOLFOXIRI plus panitumumab (pmab) followed by evaluation for resection, in patients (pts) with metastatic KRAS wild-type colorectal cancer (mCRC) with liver metastases only. 2014
- PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. 31:4349-U77. 2013
- Adverse changes in body composition of cancer surivors with BRCA mutations. 2013
- Disparities between young and elderly patients in the first course of treatment for stage II and III rectal cancers. 2013
- Dovitinib as second-line therapy in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or non-mutated advanced and/or metastatic endometrial cancer (EC): A single-arm, multicenter, phase II study. 2013
- Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses 2013
- First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type (WT) non-small cell lung cancer (NSCLC) 2013
- Predictors of outcome for pemetrexed (Pem) in metastatic NSCLC (mNSCLC). 2013
- Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study. 31:1554-1561. 2013
- Absence of interaction of cabazitaxel on the pharmacokinetics of midazolam: Results of a drug-drug interaction study in patients with advanced solid tumors 2013
- Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non-Small-Cell Lung Cancer: Results of a Phase I/II Trial. 30:3953-3959. 2012
- Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial. 30:2063-2069. 2012
- Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial. 30:2055-2062. 2012
- Amrubicin and carboplatin with pegfilgrastim in patients with extensive-stage small-cell lung cancer (ES-SCLC): A phase II study of the Sarah Cannon Research Institute (SCRI). 2012
- Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET) 2012
- Predicting length of survival for adult, outpatient oncology patients using clinic visit data 2012
- Safety and feasibility of salvage robot-assisted radical prostatectomy for recurrent prostate cancer 2012
- Safety and feasibility of salvage robot-assisted radical prostatectomy for recurrent prostate cancer. 2012
- Small business technology transfer (STTR) phase I study (1 R41 MD006148-01) of an automated voice response (AVR) system to improve symptom management in neuro-oncology patients 2012
- Histiocytic Sarcoma Arising From Clonally Related Mantle Cell Lymphoma. 30:E49-E53. 2012
- Diffuse Osteosclerosis-Associated Acute Myeloid Leukemia. 30:E3-E4. 2012
- Phase IB Study of Gene-Mediated Cytotoxic Immunotherapy Adjuvant to Up-Front Surgery and Intensive Timing Radiation for Malignant Glioma. 29:3611-3619. 2011
- OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) 2011
- Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial. 29:2215-2222. 2011
- Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study 2011
- Clinical predictors of prolonged clinical benefit (PCB) from pemetrexed (P) therapy in metastatic non-small cell lung cancer (mNSCLC) 2011
- Clinical predictors of prolonged clinical benefit (PCB) from pemetrexed (P) therapy in metastatic non-small cell lung cancer (mNSCLC) 2011
- Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses. 2011
- OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). 2011
- Personalized Medicine in Non-Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor-Targeted Therapy?. 28:4769-4777. 2010
- A phase I trial of vorinostat in combination with bevacizumab and irinotecan in recurrent glioblastoma 2010
- A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer 2010
- Chemoradiation followed by adjuvant hysterectomy for the treatment of stage IB-2 cervical cancer: 10-year experience 2010
- Effect of pelvic exenteration type and vaginal reconstruction on quality of life 2010
- Effect of tolfenamic acid on ovarian cancer cell growth, targeting of specificity protein transcription factors, and expression of c-Met and survivin 2010
- Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study 2010
- Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer. 28:2598-2603. 2010
- If Histology Matters ... 2010
- Adenocarcinoma of Colon Presenting As Cushing's Syndrome 2010
- Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non-Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial. 28:744-752. 2010
- Safety of Bevacizumab in Patients With Non-Small-Cell Lung Cancer and Brain Metastases. 27:5255-5261. 2009
- Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer. 27:4787-4792. 2009
- Three-Dimensional Prostate Mapping Biopsy Has a Potentially Significant Impact on Prostate Cancer Management. 27:4321-4326. 2009
- Carcinomatous Meningitis in Non-Small-Cell Lung Cancer: Response to High-Dose Erlotinib. 27:E31-E32. 2009
- Re-Evaluating Duration of Therapy in Advanced Non-Small-Cell Lung Cancer: Is It Really Duration or Is It More About Timing and Exposure? 2009
- Molecular characterization of highly tumorigenic cell lines used in a xenograph model to investigate cellular therapy for the treatment of refractory ovarian cancer 2009
- Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC) 2009
- Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+locally advanced breast cancer with SPARC correlatives 2009
- Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy. 27:235-241. 2009
- Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen-Identical Sibling Transplants for Adults With Leukemia. 26:5728-5734. 2008
- Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC) 2008
- Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (nab paclitaxel) and carboplatin in HER2+locally advanced breast cancer 2008
- Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic Conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. 26:2457-2463. 2008
- The association of ERCC1 and clinical outcomes of women with advanced ovarian cancer 2008
- Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. 26:650-656. 2008
- Duration of first-line chemotherapy in advanced non-small-cell lung cancer: Less is more in the era of effective subsequent therapies 2007
- Limited-stage small-cell lung cancer: The current status of combined-modality therapy 2007
- Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non-small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. 25:3448-3455. 2007
- Management of ovarian stromal cell tumors 2007
- A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer 2007
- A retrospective safety and efficacy analysis of combination therapy using Gliadel wafers plus external beam radiation therapy with concurrent temozolomide in newly diagnosed glioblastoma multiforme patients 2007
- Phase II trial of single-agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash 2007
- Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC) 2007
- Temporal dependence of the effect of radiation on erlotinib-induced skin rash 2007
- Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer. 25:1621-1623. 2007
- Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts 2006
- Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan. 24:4939-4940. 2006
- Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. 24:4825-4832. 2006
- Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. 24:4840-4847. 2006
- A comparison of combination docetaxel/carboplatin versus sequential docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer. 2006
- Safety and tolerance of multiple weekly intracavitary injections of 1311-chlorotoxin (TM-601): Preliminary results of a prospective clinical trial in patients with recurrent glioblastorna multiforme. 2006
- Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: Report from the Cancer and Leukemia Group B. 24:407-412. 2006
- Anti-epidermal growth factor (EGFR) antibody, cetuximab, in patients with stage IV colorectal carcinoma who failed all standard therapy: Final report of an access protocol. 2005
- Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. 23:832-841. 2005
- Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. 22:4837-4845. 2004
- Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: Report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. 22:4329-4340. 2004
- Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: A dose-escalation phase I trial. 22:4341-4350. 2004
- Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: A prognostic factor analysis. 22:3798-3804. 2004
- Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. 22:3507-3516. 2004
- Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: Phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. 22:2891-2900. 2004
- Doxil and gemcitabine combination therapy for recurrent ovarian cancer: Results of a phase II trial. 2004
- Use of thalidomide as consolidation therapy in ovarian and primary peritoneal cancers. 2004
- F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. 21:3995-4000. 2003
- Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. 21:1485-1491. 2003
- Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. 20:1335-1343. 2002
- Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer. 19:1078-1087. 2001
- IMMUNOTOXINS - A CLINICAL REVIEW OF THEIR USE IN THE TREATMENT OF MALIGNANCIES 1989
Research
category
- ONCOLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 0732-183X
Electronic International Standard Serial Number (EISSN)
- 1527-7755
Other
journal abbreviation
- J CLIN ONCOL